Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus UTICILLIN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus UTICILLIN VK.
AMPICILLIN TRIHYDRATE vs UTICILLIN VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity.
Uticillin VK (penicillin V potassium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) in the bacterial cytoplasmic membrane, thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
250-500 mg PO q6h or 1-2 g IV/IM q4-6h; up to 12 g/day IV for severe infections.
250-500 mg orally every 6-8 hours for 10 days for streptococcal pharyngitis; 250-500 mg orally every 6 hours for pneumococcal infections.
None Documented
None Documented
Terminal elimination half-life 1-1.8 hours; prolonged in renal impairment (up to 10-20 hours in anuria)
0.5-1.0 hour (prolonged in renal impairment; e.g., up to 10 hours in anuria)
Renal: 75-90% unchanged; biliary: small amount; fecal: negligible
Renal: 70-80% unchanged via tubular secretion and glomerular filtration; biliary/fecal: minor (about 10%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic